Cleveland Clinic | Strategic Alliance Partners

Cleveland Clinic Cancer Institute provides complete cancer care enhanced by innovative basic, clinical and translational research. It offers the most effective techniques to achieve long-term survival and improve patients’ quality of life. Cleveland Clinic Cancer Institute’s more than 800 physicians, researchers, nurses and technicians care for thousands of patients each year and provide access to a wide range of clinical trials. Cleveland Clinic Cancer Institute has a global presence, uniting clinicians based in our Cancer Institute, Cleveland Clinic’s other patient-centered institutes, our regional hospitals and health centers, and our operations in Florida, London and Abu Dhabi. Cleveland Clinic is a nonprofit, multi-specialty academic medical center with more than 5,000 staff physicians and researchers who integrate outpatient and hospital care with research and education for better patient outcomes and experience. Cleveland Clinic is a trusted healthcare leader. We’re recognized in the U.S. and throughout the world for our expertise and care.

Be sure to tune into our Cancer Advances podcast where we explore the latest innovative research and clinical advances in the field of oncology. Listen now!

Connect with us:

Latest from Cleveland Clinic

Educating on Multiple Myeloma: Patient and Physician Resources

August 21, 2023

Video

Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.

Multiple Myeloma: Challenges in Diagnosis and Role of Multidisciplinary Care

August 21, 2023

Video

Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.

Dr Roof on Disparities in Lung Cancer Mortality Rates in the United States

July 27, 2023

Video

Logan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.

Unmet Needs and Clinical Pearls in the Treatment of HER2+ mBC

July 20, 2023

Video

Megan Kruse, MD, offers advice to community oncologists treating HER2+ metastatic breast cancer and discusses unmet needs in the treatment landscape.

Dr Gupta on Criteria for the EV-103 Trial in Advanced Urothelial Cancer

July 13, 2023

Video

Shilpa Gupta, MD, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma, and highlights next steps for the investigation of the frontline combination of enfortumab vedotin and pembrolizumab in the phase 3 EV-302 trial.

Ongoing Research in HER2+ Metastatic Breast Cancer

July 13, 2023

Video

An overview of agents and treatment strategies currently being investigated in HER2+ metastatic breast cancer.

HER2CLIMB-02: Tucatinib and T-DM1 in HER2+ Breast Cancer

July 13, 2023

Video

Megan Kruse, MD, discusses the HER2CLIMB-02 study and the impact it may have on the HER2+ metastatic breast cancer treatment landscape.

Dr Gastman on Exploratory Biomarker Analysis of the Checkmate76K Trial in Stage IIB/C Melanoma

July 12, 2023

Video

Brian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.

Unmet Needs and Future Perspectives in Treatment of MDS

July 06, 2023

Video

Expert oncologists discuss unmet needs and share final thoughts on the future of treatment of patients with lower-risk MDS.

Treating HER2+ Breast Cancer with CNS Involvement

July 06, 2023

Video

Clinical insights on approaches to treating HER2+ metastatic breast cancer with central nervous system involvement.

Clinical Management of Patients with Lower-risk MDS

July 06, 2023

Video

Ralph Boccia, MD, FACP, highlights emerging therapies and the importance of next-generation sequencing for patients with MDS.

Updates from ASCO 2023 in HER2+ Metastatic Breast Cancer

July 06, 2023

Video

Megan Kruse, MD, reviews clinical trial data updates from the 2023 ASCO Annual Meeting on HER2+ metastatic breast cancer.

Emerging Therapies for Treatment of MDS

June 29, 2023

Video

Expert oncologists discuss management strategies for patients with lower-risk MDS considering upcoming treatment options.

Data Updates from SABCS 2022 in HER2+ Metastatic Breast Cancer

June 29, 2023

Video

An expert on HER2+ metastatic breast cancer reviews data from the DESTINY-Breast02 and DESTINY-Breast03 trials, which were updated at the 2022 San Antonio Breast Cancer Symposium.

Safety and Efficacy of Luspatercept in Frontline Setting in Patients with MDS

June 29, 2023

Video

Oncologists review study design and discuss key safety and efficacy data of the COMMANDS trial investigating luspatercept in frontline setting in patients with lower-risk MDS.

Evolving Treatment Strategies for HER2+ Metastatic Breast Cancer

June 29, 2023

Video

Megan Kruse, MD, discusses the evolving treatment landscape for patients with HER2+ metastatic breast cancer.

Dr Gupta on the MAIN-CAV Trial of Maintenance Cabozantinib Plus Avelumab in mUC

June 27, 2023

Video

Shilpa Gupta, MD, discusses the design, methodology, and potential significance of the ongoing phase 3 MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma

Clinical Use of Luspatercept on Patients with Lower-risk MDS

June 22, 2023

Video

Ralph Boccia, MD, FACP, shares his clinical experience using luspatercept to treat patient with lower-risk MDS.

Frontline Treatment Options for Lower-Risk MDS

June 22, 2023

Video

Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.

Dr Gupta on the 4-Year Efficacy of the EV-103 Trial in Urothelial Carcinoma

June 15, 2023

Video

Shilpa Gupta, MD, discusses the 4-year safety and efficacy data derived from the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma.